This Phase 2 study will investigate the safety and clinical activity of XmAb20717 alone or in
combination with standard of care anticancer therapies in patients with metastatic
castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior
lines of anticancer therapy.
This is a Phase 2, open-label, multiple-dose, multiple-arm, parallel assignment study in
patients with mCRPC who have progressed after treatment with at least 2 prior lines of
anticancer therapy. It will enroll subjects into one of 5 molecularly defined cohorts based
on the results of acceptable, documented prior diagnostic testing:
Cohort A: Aggressive variant (anaplastic) adenocarcinoma of the prostate (AVPCa)
Cohort B: Homologous recombination deficient (HRD)/cyclin-dependent kinase 12 (CDK12)
mutation positive tumors that have progressed on poly-adenosine diphosphate ribose
polymerase inhibitors (HRD/CDK12 PARP Progressors)
Cohort C: HRD/CDK12 mutation positive tumors not previously treated with PARP inhibitors
(HRD/CDK12 PARP Naïve)
Subjects will receive XmAb20717 alone (Cohort D) or in combination with standard therapy
(XmAb20717 + carboplatin + cabazitaxel [or docetaxel if no prior treatment]: Cohorts A, B,
and E; XmAb20717 + olaparib: Cohort C).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.